APR 24, 2019 10:47 PM PDT

A Shrub Compound Reveals New Avenue for Treatment Addictions

WRITTEN BY: Nouran Amin

A compound found in a native African shrub revealed three major types of the serotonin transporter—a protein in the brain that is implicated in anxiety and depression. The serotonin protein binds to a naturally occurring alkaloid known as ibogaine and is involved in altering brain function.

Using cryo-electron microscopy, OHSU researchers reveal the three major shapes of the serotonin transporter--a protein in the brain linked to anxiety and depression. In this image, a serotonin transporter bound with ibogaine (lime spheres), is found to have outward-open, closed and inward-open shapes. (OHSU)

Through cryo-electron microscopy, scientists revealed the structure of the serotonin transporter in its outward-open, closed and inward-open shapes. The cryo-EM enables scientists to observe molecular interaction near-atomic detail. The serotonin transporter is one of the smallest molecules to be so clearly visualized through cryo-EM. "It means we can target different states of the transporter to modulate its activity," said senior author Eric Gouaux, Ph.D., senior scientist at the OHSU Vollum Institute in Portland, Oregon, and an investigator with the Howard Hughes Medical Institute. "It opens up new thinking of how you might come up with novel molecules to bind to the transporter."

Serotonin is a neurotransmitter that influences much of human behavior and regulates the central nervous system including processes ranging from cardiovascular function to digestion, body temperature, endocrinology and reproduction. It works to shape neurological processes such as sleep, mood, cognition, pain, hunger and aggression. The serotonin transporter serves as the molecular pump for serotonin and works to recycle the neurotransmitter following signaling.

Findings of the study were reported in Nature which describe the mechanism behind how the serotonin receptor binds to ibogaine which can open new possibilities to developing new therapeutics that can stop addiction without the hallucinogenic and harmful properties of ibogaine.

"There's a real need to develop molecules that have these anti-addictive properties," said co-lead author Jonathan Coleman, Ph.D., a researcher in the OHSU Vollum Institute.

"Most antidepressant drugs bind to the outward-open conformation, and our study shows ibogaine can bind to the inward state," said co-lead author Dongxue Yang, Ph.D., a researcher in Gouaux's lab. "It provides many more avenues to design small molecules with anti-addictive properties," Coleman added.

Source: Science Daily

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
JAN 07, 2019
Cell & Molecular Biology
JAN 07, 2019
Researchers Develop an Experimental Therapy for Triple-negative Breast Cancer
Between 12 and 17% of all breast cancer cases are triple-negative, a highly aggressive type with few therapeutic options....
JAN 12, 2019
Drug Discovery
JAN 12, 2019
The Harms of Prescription Sleeping Pills
In a study published by Frontiers in Behavioral Neuroscience, one of the main class of prescription sleeping pills was found to reduce the ability to wake...
FEB 17, 2019
Drug Discovery
FEB 17, 2019
Drug Improves Muscle Properties
Currently, adults over 65 are an increasingly growing segment in many countries. In the United States, the elderly population will increase by 40 percent w...
MAR 10, 2019
Drug Discovery
MAR 10, 2019
Can Green Tea Reverse Memory Impairment?
In a study published in the Journal of Biological Chemistry, a diet containing green tea and carrots reversed Alzheimer's-like symptoms in mice that ar...
MAR 25, 2019
Drug Discovery
MAR 25, 2019
Aspirin Combats Tuberculosis
Tuberculosis is a global infection far from being eradicated. It currently infects more than 1,400 people per year in Australia. The deadliest form and exp...
MAR 25, 2019
Drug Discovery
MAR 25, 2019
Investigational Drug Reverses High Cholesterol and Non-Alcoholic Fatty Liver Disease
A novel molecular pathway was recently discovered for an enzyme inhibitor in humans that is implicated in the development of high cholesterol and nonalcoho...
Loading Comments...